Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Healthtrust
Colorcon
Moodys
Fish and Richardson
Accenture
Cerilliant
Julphar
Medtronic
US Department of Justice

Generated: February 24, 2018

DrugPatentWatch Database Preview

Glaxosmithkline Con Company Profile

« Back to Dashboard

Summary for Glaxosmithkline Con
International Patents:314
US Patents:11
Tradenames:11
Ingredients:11
NDAs:12

Drugs and US Patents for Glaxosmithkline Con

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 9,320,862 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 6,858,596 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-001 May 18, 2009 OTC Yes No 8,501,164 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 7,541,350 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons PREVACID 24 HR lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 022327-001 May 18, 2009 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 7,101,866 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE ALLERGY RELIEF fluticasone propionate SPRAY, METERED;NASAL 205434-001 Jul 23, 2014 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes 8,501,164 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Glaxosmithkline Con

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 4,943,565 ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-001 May 18, 2009 5,110,605 ➤ Try a Free Trial
Glaxosmithkline Con TRANSDERM SCOP scopolamine FILM, EXTENDED RELEASE;TRANSDERMAL 017874-001 Approved Prior to Jan 1, 1982 4,031,894 ➤ Try a Free Trial
Glaxosmithkline Cons ALLI orlistat CAPSULE;ORAL 021887-001 Feb 7, 2007 4,598,089 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 5,856,355*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 6,121,314*PED ➤ Try a Free Trial
Glaxosmithkline Cons ALLI orlistat CAPSULE;ORAL 021887-001 Feb 7, 2007 6,004,996 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 4,755,534*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 6,005,001*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 5,681,849*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CON drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gum 2 mg ➤ Subscribe 1/22/2013
➤ Subscribe Gum 4 mg ➤ Subscribe 1/22/2013
➤ Subscribe Capsules 60 mg ➤ Subscribe 9/8/2010

Non-Orange Book US Patents for Glaxosmithkline Con

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,592,329 Crystalline complexes of fluticasone-2-furoate ➤ Try a Free Trial
6,537,983 Anti-inflammatory androstane derivatives ➤ Try a Free Trial
6,777,399 Anti-inflammatory androstane derivative compositions ➤ Try a Free Trial
7,125,985 Compounds useful in the manufacture of an anti-inflammatory androstane derivative ➤ Try a Free Trial
7,531,528 Formulation containing anti-inflammatory androstane derivatives ➤ Try a Free Trial
6,777,400 Anti-inflammatory androstane derivative compositions ➤ Try a Free Trial
6,858,593 Anti-inflammatory androstane derivative compositions ➤ Try a Free Trial
7,132,532 Compounds useful in the manufacture of an anti-inflammatory androstane derivative ➤ Try a Free Trial
6,878,698 Anti-inflammatory androstane derivatives ➤ Try a Free Trial
6,787,532 Formulation containing anti-inflammatory androstane derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Glaxosmithkline Con Drugs

Supplementary Protection Certificates for Glaxosmithkline Con Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/008 Ireland ➤ Try a Free Trial PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
1305329/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
2008 00022 Denmark ➤ Try a Free Trial
C0014 France ➤ Try a Free Trial PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
C0042 Belgium ➤ Try a Free Trial PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
C0067 France ➤ Try a Free Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
C011/2008 Ireland ➤ Try a Free Trial SPC011/2008: 20081105, EXPIRES: 20230110
0343 Netherlands ➤ Try a Free Trial 300343, 20210803, EXPIRES: 20230110
429 Luxembourg ➤ Try a Free Trial 91429, EXPIRES: 20230111
269 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKinsey
Argus Health
Deloitte
Fuji
Johnson and Johnson
Federal Trade Commission
Covington
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot